Treatments directly preceding canakinumab initiation, n (%) | Overall (N=133) | Children (N=65) | Adults (N=68) | PFS subtypes | |||
---|---|---|---|---|---|---|---|
CAPS (n=52) | TRAPS (n=37) | HIDS/MKD (n=10) | FMF (n=39) | ||||
Nonsteroidal anti-inflammatory drugs | 37 (27.8) | 25 (38.5) | 12 (17.6) | 19 (36.5) | 7 (18.9) | 4 (40.0) | 9 (23.1) |
Colchicine | 29 (21.8) | 13 (20.0) | 16 (23.5) | 10 (19.2) | 3 (8.1) | 2 (20.0) | 14 (35.9) |
Oral corticosteroids | 23 (17.3) | 13 (20.0) | 10 (14.7) | 8 (15.4) | 7 (18.9) | 1 (10.0) | 8 (20.5) |
Methotrexate | 19 (14.3) | 3 (4.6) | 16 (23.5) | 5 (9.6) | 8 (21.6) | 0 (0.0) | 6 (15.4) |
Corticosteroid injection | 7 (5.3) | 3 (4.6) | 4 (5.9) | 0 (0.0) | 6 (16.2) | 0 (0.0) | 1 (2.6) |
Thalidomide | 1 (0.8) | 1 (1.5) | 0 (0.0) | 1 (1.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Biologics | |||||||
 Anakinra | 32 (24.1) | 22 (33.8) | 10 (14.7) | 17 (32.7) | 6 (16.2) | 3 (30.0) | 9 (23.1) |
 Adalimumab | 12 (9.0) | 3 (4.6) | 9 (13.2) | 4 (7.7) | 5 (13.5) | 1 (10.0) | 3 (7.7) |
 Etanercept | 9 (6.8) | 4 (6.2) | 5 (7.4) | 3 (5.8) | 3 (8.1) | 1 (10.0) | 2 (5.1) |
 Infliximab | 6 (4.5) | 4 (6.2) | 2 (2.9) | 1 (1.9) | 3 (8.1) | 1 (10.0) | 1 (2.6) |
 Rilonacept | 6 (4.5) | 2 (3.1) | 4 (5.9) | 5 (9.6) | 0 (0.0) | 1 (10.0) | 0 (0.0) |
 Rituximab | 2 (1.5) | 0 (0.0) | 2 (2.9) | 1 (1.9) | 0 (0.0) | 1 (10.0) | 0 (0.0) |
 Tocilizumab | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unknown | 2 (1.5) | 0 (0.0) | 2 (2.9) | 1 (1.9) | 0 (0.0) | 0 (0.0) | 1 (2.6) |